ES2538706T3 - Procedimiento de purificación del factor de coagulación VIII - Google Patents

Procedimiento de purificación del factor de coagulación VIII Download PDF

Info

Publication number
ES2538706T3
ES2538706T3 ES12179389.7T ES12179389T ES2538706T3 ES 2538706 T3 ES2538706 T3 ES 2538706T3 ES 12179389 T ES12179389 T ES 12179389T ES 2538706 T3 ES2538706 T3 ES 2538706T3
Authority
ES
Spain
Prior art keywords
fviii
resin
purification
stage
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12179389.7T
Other languages
English (en)
Spanish (es)
Inventor
Carin Borgvall
Ulrika Ericsson
Gustav Gilljam
Mats Jernberg
Stefan Winge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma AG
Original Assignee
Octapharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40076764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2538706(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma AG filed Critical Octapharma AG
Application granted granted Critical
Publication of ES2538706T3 publication Critical patent/ES2538706T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
ES12179389.7T 2008-06-24 2009-06-24 Procedimiento de purificación del factor de coagulación VIII Active ES2538706T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12940208P 2008-06-24 2008-06-24
US129402P 2008-06-24
EP08158893 2008-06-24
EP08158893 2008-06-24

Publications (1)

Publication Number Publication Date
ES2538706T3 true ES2538706T3 (es) 2015-06-23

Family

ID=40076764

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09769279T Active ES2391613T3 (es) 2008-06-24 2009-06-24 Un procedimiento para purificar el factor de coagulación VIII
ES12179389.7T Active ES2538706T3 (es) 2008-06-24 2009-06-24 Procedimiento de purificación del factor de coagulación VIII

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09769279T Active ES2391613T3 (es) 2008-06-24 2009-06-24 Un procedimiento para purificar el factor de coagulación VIII

Country Status (19)

Country Link
US (1) US8329871B2 (enExample)
EP (2) EP2537862B1 (enExample)
JP (1) JP5619738B2 (enExample)
KR (3) KR101804136B1 (enExample)
CN (1) CN102066417B (enExample)
AU (1) AU2009264282B2 (enExample)
BR (1) BRPI0914695B1 (enExample)
CA (1) CA2728047C (enExample)
DK (2) DK2537862T3 (enExample)
ES (2) ES2391613T3 (enExample)
IL (3) IL209758A (enExample)
MX (1) MX2010013908A (enExample)
PL (1) PL2300497T3 (enExample)
PT (1) PT2300497E (enExample)
RU (2) RU2698392C2 (enExample)
SI (1) SI2300497T1 (enExample)
UA (1) UA100901C2 (enExample)
WO (1) WO2009156430A1 (enExample)
ZA (1) ZA201009162B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167526B1 (en) 2007-07-11 2011-03-30 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
KR101691443B1 (ko) * 2008-09-03 2016-12-30 옥타파마 아게 재조합에 의해 제조된 인자 ⅷ을 위한 신규한 보호 조성물
EP2326658A4 (en) * 2008-09-12 2013-04-10 Ge Healthcare Bio Sciences Ab REMOVAL OF REINFORCED PROTEIN AGGREGATES WITH MULTIMODAL ANION DERIVATIVES IN THE PRESENCE OF TWITTERS WITHOUT PROTEINS
CN102858797B (zh) * 2010-03-30 2016-05-11 奥克塔法马股份有限公司 纯化生长因子蛋白的方法
TR201911082T4 (tr) * 2010-03-30 2019-08-21 Octapharma Ag K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
ES2639641T3 (es) 2010-04-20 2017-10-27 Octapharma Ag Nuevo agente estabilizante para proteínas farmacéuticas
WO2012049285A1 (en) 2010-10-14 2012-04-19 Octapharma Ag A method for the quantitative glycosylation analysis of proteins
JP5947802B2 (ja) * 2010-11-05 2016-07-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ミックスモードクロマトグラフィーによる抗体捕捉の最適化方法
KR101980164B1 (ko) * 2011-05-13 2019-05-20 옥타파마 아게 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법
ES2613723T3 (es) 2011-06-17 2017-05-25 School Juridical Person Higashi-Nippon-Gakuen Método de medición del tiempo de coagulación sanguínea para detectar anticoagulantes de Lupus
EP2771358A4 (en) * 2011-10-26 2015-08-26 Bio Rad Laboratories ELIMINATION OF VIRAL AGENTS IN MIXED MODE CHROMATOGRAPHY
AU2013334644B2 (en) * 2012-10-24 2018-07-12 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
US20140154233A1 (en) * 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
CN103880947B (zh) * 2012-12-21 2016-01-13 武汉禾元生物科技股份有限公司 一种分离纯化高纯度重组人血清白蛋白的层析方法
HK1219964A1 (zh) 2013-03-08 2017-04-21 Genzyme Corporation 治疗性蛋白药物物质的整合连续制造
US20160130361A1 (en) * 2013-06-13 2016-05-12 Biogen Ma Inc. Anti-factor viii antibodies or uses thereof
CA2910770C (en) 2013-07-12 2018-02-27 Merck Patent Gmbh Removal of fragments from a sample containing a target protein using activated carbon
EP3043813B1 (en) * 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
KR101988705B1 (ko) 2013-09-24 2019-06-12 화이자 인코포레이티드 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI671312B (zh) * 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
EP3097118B1 (en) * 2014-01-20 2018-07-18 Octapharma AG A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
CA2936829C (en) * 2014-01-24 2024-05-28 Am-Pharma B.V. Downstream processing of an alkaline phosphatase
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
CN104861060A (zh) * 2014-02-21 2015-08-26 神州细胞工程有限公司 一种纯化凝血因子viii的方法
CN106232614A (zh) 2014-05-29 2016-12-14 新加坡科技研究局 蛋白质提取方法
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
WO2016207328A1 (en) * 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
EP3205665A1 (en) 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
GB201617240D0 (en) * 2016-10-11 2016-11-23 Profactor Pharma Ltd Purification process
CN111183151B (zh) * 2017-06-23 2024-06-07 武田药品工业株式会社 因子viii亚种的纯化
CN107226859B (zh) * 2017-08-10 2020-11-24 博雅生物制药集团股份有限公司 一种人凝血因子ⅷ的制备方法
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
AU2019332764B2 (en) 2018-08-31 2025-05-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
EP4093745A4 (en) * 2020-01-20 2024-03-06 Wuxi Biologics Ireland Limited NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY
CN118217951B (zh) * 2024-04-01 2025-05-23 山东建筑大学 一种水中的高纯度磷回收装置和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US5316680A (en) * 1992-10-21 1994-05-31 Cornell Research Foundation, Inc. Multimodal chromatographic separation media and process for using same
JPH08506710A (ja) 1993-06-11 1996-07-16 ノーザン・テレコム・リミテッド ユーザ制御呼管理サービス方法および装置
DE4337573C1 (de) * 1993-11-04 1995-05-18 Octapharma Ag Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
AUPR638801A0 (en) * 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
WO2005082483A1 (en) * 2004-02-27 2005-09-09 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
PL1765866T3 (pl) * 2004-06-07 2014-06-30 Therapure Biopharma Inc Wydzielanie białek osocza lub surowicy
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
FR2887883B1 (fr) * 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
WO2008008975A2 (en) * 2006-07-14 2008-01-17 Genentech, Inc. Refolding of recombinant proteins
RU2324495C1 (ru) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения препарата фактора свертывания viii крови человека
CA2674881A1 (en) * 2007-02-01 2008-08-07 Baxter International Inc. Fviii-independent fix-mutant proteins for hemophilia a treatment
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
EP2167526B1 (en) * 2007-07-11 2011-03-30 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
BRPI0914695A2 (pt) 2015-10-20
KR20110038634A (ko) 2011-04-14
JP5619738B2 (ja) 2014-11-05
MX2010013908A (es) 2011-01-21
US20110160435A1 (en) 2011-06-30
BRPI0914695B1 (pt) 2022-04-19
DK2537862T3 (en) 2015-06-15
UA100901C2 (ru) 2013-02-11
CA2728047C (en) 2019-07-30
SI2300497T1 (sl) 2013-02-28
RU2015141849A (ru) 2018-12-28
KR20160104740A (ko) 2016-09-05
RU2011102437A (ru) 2012-07-27
PT2300497E (pt) 2012-10-30
EP2537862B1 (en) 2015-03-18
ZA201009162B (en) 2011-10-26
CN102066417B (zh) 2015-11-25
RU2015141849A3 (enExample) 2018-12-28
IL229583A0 (en) 2014-01-30
EP2300497B1 (en) 2012-08-08
IL209758A0 (en) 2011-02-28
PL2300497T3 (pl) 2013-02-28
CA2728047A1 (en) 2009-12-30
KR101700722B1 (ko) 2017-01-31
KR101804136B1 (ko) 2017-12-04
AU2009264282A1 (en) 2009-12-30
RU2698392C2 (ru) 2019-08-26
RU2567811C2 (ru) 2015-11-10
EP2537862A1 (en) 2012-12-26
IL209758A (en) 2014-02-27
KR20170102065A (ko) 2017-09-06
AU2009264282B2 (en) 2013-04-18
EP2300497A1 (en) 2011-03-30
CN102066417A (zh) 2011-05-18
WO2009156430A1 (en) 2009-12-30
ES2391613T3 (es) 2012-11-28
IL229583B (en) 2018-03-29
DK2300497T3 (da) 2012-10-29
US8329871B2 (en) 2012-12-11
JP2011525523A (ja) 2011-09-22

Similar Documents

Publication Publication Date Title
ES2538706T3 (es) Procedimiento de purificación del factor de coagulación VIII
Zhou et al. A quantitative investigation into the losses of proteins at different stages of a two‐dimensional gel electrophoresis procedure
Chevalier Highlights on the capacities of" Gel-based" proteomics
Tsung Creatine kinase isoenzyme patterns in human tissue obtained at surgery.
Huang et al. Capillary electrophoresis‐based separation techniques for the analysis of proteins
Ahmed et al. Strategies for revealing lower abundance proteins in two-dimensional protein maps
ES2388219T3 (es) Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum
Wu et al. An improved western blotting technique effectively reduces background
Hwa et al. Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis
Moritz et al. Application of 2‐D free‐flow electrophoresis/RP‐HPLC for proteomic analysis of human plasma depleted of multi high‐abundance proteins
Chiou et al. Evaluation of commonly used electrophoretic methods for the analysis of proteins and peptides and their application to biotechnology
Lind et al. Post translational modifications in adenovirus type 2
Nakagawa et al. Optimization and application of silver staining of non-glycosylated and glycosylated proteins and nucleic acids for agarose native gel electrophoresis
Naryzhny Blue Dry Western: simple, economic, informative, and fast way of immunodetection
Rasmussen et al. Two‐dimensional electrophoretic analysis of human breast carcinoma proteins: Mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2
ATE322688T1 (de) Verfahren zur bestimmung der nitrosylierung von proteinen
Wang et al. Enhanced ELISA detection by target protein enrichment with MIP: A new strategy for ultra-sensitive protein detection
Meng et al. Moving affinity boundary electrophoresis and its selective isolation of histidine in urine
Brgles et al. Selectivity of monolithic supports under overloading conditions and their use for separation of human plasma and isolation of low abundance proteins
Sahab et al. Anion exchange fractionation of serum proteins versus albumin elimination
Jiang et al. Two-dimensional southwestern blotting and characterization of transcription factors on-blot
Buneeva et al. Quantitative affinity interaction of ubiquitinated and non-ubiquitinated proteins with proteasome subunit Rpn10
Farina-Gomez et al. Sample preparation of serum to allow capillary electrophoresis analysis of prostate specific antigen isoforms
Liu et al. Proteomics analysis of porcine serum proteins by LC-MS/MS after foot-and-mouth disease virus (FMDV) infection
US20020153252A1 (en) Multi-dimensional proteomic analysis method